An open-label study of the effect of PEGASYS [peginterferon alfa-2a] on sustained virologic response in patients with chronic hepatitis C receiving ribavirin combination therapy.

Trial Profile

An open-label study of the effect of PEGASYS [peginterferon alfa-2a] on sustained virologic response in patients with chronic hepatitis C receiving ribavirin combination therapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2010

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 04 Jun 2010 Additional trial locations (Bosnia and Herzegovina, Czech Republic, Slovakia) identified as reported by Roche record.
    • 23 Feb 2010 Status changed from recruiting to completed as reported by Roche record.
    • 20 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top